重组人粒细胞刺激因子注射液不同给药途径对白血病化学治疗患者的影响
| 作者: |
1宋文艳,
2张丽军,
3阚文超,
4田明杰,
2成志勇,
2王亚丽,
2张岚
1 高阳县医院内科，河北 高阳 071500 2 保定市第一医院血液内科，河北 保定 071000 3 唐山学院医务室，河北 唐山 063000 4 河北大学附属医院血液内科，河北 保定 071000 |
| 通讯: |
田明杰
Email: 2530135881@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2018.01.013 |
摘要
目的：研究皮下注射与静脉注射重组人粒细胞刺激因子(recombinant human granulocyte colony-stimulating factor，rhG-CSF)注射液两组不同给药途径对急性白血病化学治疗后骨髓抑制期患者的影响。方法：选取保定市第一医院及河北大学附属医院200例急性白血病化学治疗后患者，依据rhG-CSF不同给药途径，分为皮下注射组与静脉注射组，每组各100例。观察两组患者治疗后粒细胞缺乏恢复时间、不良反应发生率及治疗配合度。结果：两组患者粒细胞缺乏恢复时间差异无统计学意义(P>0.05)。静脉注射组患者局部感染发生率、出血发生率明显低于皮下注射组；静脉注射组疼痛评分显著低于皮下注射组，而配合度高于皮下注射组(均P<0.05)。结论：静脉注射rhG-CSF较皮下注射可减少局部感染及出血等不良反应，并缓解患者痛苦，提高患者依从性。
关键词：
重组人粒细胞刺激因子；白血病；静脉注射；皮下注射
Effect of recombinant human granulocyte colony-stimulating factor injection in different routes on patients with leukemia chemotherapy
CorrespondingAuthor: TIAN Mingjie Email: 2530135881@qq.com
DOI: 10.3978/j.issn.2095-6959.2018.01.013
Abstract
Objective: To study the effect of subcutaneous injection and intravenous injection of recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) on bone marrow suppression in patients with acute leukemia after chemotherapy. Methods: A total of 200 cases of acute leukemia patients treated with chemotherapy from the First Hospital of Baoding and Affiliated Hospital of Hebei University were selected. According the different routes of rhG-CSF injection, 200 cases were divided into subcutaneous injection group and intravenous injection group (100 cases in each group). The recovery time of agranulocytosis, incidence of adverse reactions and treatment compliance were observed with two groups of patients. Results: There was no significant difference between the two groups in the recovery time (P>0.05). The incidence of local infection and the incidence of hemorrhage in the intravenous injection group were significantly lower than those in the subcutaneous injection group; the pain score of the intravenous injection group was significantly lower than that of the subcutaneous injection group, and the matching degree was higher than that of the subcutaneous injection group (all P<0.05). Conclusion: Compared with subcutaneous injection, intravenous injection of rhG-CSF can reduce the side effects of local infection and bleeding, and remit the pain of patients and raise compliance.
Keywords：
recombinant human granulocyte colony-stimulating factor; leukemia; intravenous injection; subcutaneous injection